contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Philip Coombes

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

BioPorto

Bioporto released preliminary figures for fiscal year 2024 yesterday after market closed.
Guidance 2024
Revenue FY 24 DKK 40 mio.
Adj ebitda loss DKK 75&#x2013;90 mio. midpoint -82,5&#xa0;
&#xa0;
Preliminary figures 2024
Revenue DKK 36,2 mio. vs. DKK 31 mio (FY23) +17% YoY and vs. Guidance -9,5%
Adj ebitda loss DKK 68-73 mio. vs. Guidance 75-90 mio.
&#xa0;Revenue for the fourth quarter DKK 7,9 mio. vs. DKK 6,6 mio (Q4-23) +20%
&#xa0;CEO in Bioporto comments &#x201c;Overall I am very satisfied with the preliminary results for 2024. Having a very ambitious revenue target, we managed to deliver solid revenue growth based on increased Research Use Only Sales of NGAL in the US. We look forward to the US commercial launch of the FDA cleared ProNephro AKI (NGAL) this year. For adjusted EBITDA, the improved estimate is primarily due to tight cost control and lower than expected costs related to our clinical study in the US for adult usage of ProNephro AKI (NGAL).&#x201d;&#xa0;
&#xa0;The company will release the annual report on March 20 &#x2013; 2025 and will participate in HC Andersen Capital seminar January 16 &#x2013; 2025.
Sign up for seminar here: <a href="https://hcaccapital-stag.agillic.eu/api/api/webcopy/view/pdxGGzYzkDEKaH0dnmoR5xOQDPZRhZYzLj6-m7vgzAv_H_zo9VLnJojkg9kk0YPf:IFpD7QxTI2AhPEenxN0e0w==/Seminar+-+16+januar+2025+-+FOR+SELSKABER.html?lgn_uid=LmEzQ0U6MTc2NDA3NTYyNsXp3jzvV4-zlgA3e8t-iIw!&amp;lgn_uid=LmEzQ0U6MTc2NDA3ODE5MlxsP6c1elsMk87F6ZrZyh0!&amp;ea=zFipDItxE1kqewoy-zH4pRFe3GmZkCSLgZqnSP3Ebafz7sduo_8i9iO4jVJToysrdU1aPhDgnBqiO9xb36CL5w==:MdGsvnHBrBoGz1RKVFvq_Q==" target="_blank" rel="noopener">HCA Capital seminar</a>
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:15 AM 06.01-2025.

HC Andersen Capital

Bioporto: Preliminary 2024 figures

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Amazon continues to grow in Sweden

Dollarns dominans – ohotad eller sårbar?  Om dollarns position som världsvaluta 